Dr. Koller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Division of Leukemia
1500 East Duarte Road
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-389-3060
Summary
- Dr. Paul Koller is an oncologist in Duarte, CA and is affiliated with City of Hope Comprehensive Cancer Center. He received his medical degree from McGovern Medical School at UTHealth and has been in practice 5 years. He specializes in hematologic oncology. He has more than 30 publications and over 350 citings.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
Baylor College of MedicineResidency, Internal Medicine, 2012 - 2015
McGovern Medical School at UTHealthClass of 2012
Certifications & Licensure
CA State Medical License 2019 - 2025
TX State Medical License 2016 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2019 Mar 11
Roles: Contact
- Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2025 Mar 20
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid ...Amanda Blackmon, Michelle Afkhami, Dongyun Yang, Sally Mokhtari, Yazeed Samara
Bone Marrow Transplantation. 2025-02-01 - TP53 Mutations are Associated with CD19 Negative Relapse and Inferior Outcomes after Blinatumomab in Adults with ALL.Ibrahim Aldoss, Shanpeng Li, Jianying Zhang, Mary C Clark, Vaibhav Agrawal
Blood Advances. 2025-01-16 - 2 citationsOlverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.Elias Jabbour, Vivian G Oehler, Paul B Koller, Omer Jamy, Elza Lomaia
JAMA Oncology. 2025-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
